291 related articles for article (PubMed ID: 12478903)
21. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
22. [Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].
Kath R; Blumenstengel K; Fricke HJ; Peters HD; Höffken K
Dtsch Med Wochenschr; 2001 Feb; 126(8):198-202. PubMed ID: 11256023
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
[TBL] [Abstract][Full Text] [Related]
24. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
25. A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
Davidson KL; Devaney MB; Tighe JE; Rogers SY; Dunlop DJ; Mackie MJ; Thomas RV; Johnson PR;
Haematologica; 2003 Dec; 88(12):1366-71. PubMed ID: 14687989
[TBL] [Abstract][Full Text] [Related]
26. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
Pavone V; Gaudio F; Guarini A; Perrone T; Zonno A; Curci P; Liso V
Bone Marrow Transplant; 2002 Feb; 29(4):285-90. PubMed ID: 11896424
[TBL] [Abstract][Full Text] [Related]
27. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.
Sym SJ; Lee DH; Kang HJ; Nam SH; Kim HY; Kim SJ; Eom HS; Kim WS; Suh C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):27-33. PubMed ID: 18839172
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
[TBL] [Abstract][Full Text] [Related]
29. [Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin].
Okamoto M; Maruyama F; Tsuzuki M; Nomura T; Miyazaki H; Wakita M; Kojima H; Sobue R; Matsui T; Ino T
Rinsho Ketsueki; 1994 Jul; 35(7):635-41. PubMed ID: 8065017
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma.
Nishimori H; Fujii N; Maeda Y; Matsuoka K; Takenaka K; Shinagawa K; Ikeda K; Matsuo K; Harada M; Tanimoto M
Anticancer Res; 2009 May; 29(5):1749-54. PubMed ID: 19443398
[TBL] [Abstract][Full Text] [Related]
31. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
[TBL] [Abstract][Full Text] [Related]
32. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
[TBL] [Abstract][Full Text] [Related]
33. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of alternating triple therapy on relapsed or refractory non-Hodgkin's lymphoma].
Tian H; Chen J; Wu Y; Li LL
Ai Zheng; 2008 Jun; 27(6):633-5. PubMed ID: 18570739
[TBL] [Abstract][Full Text] [Related]
35. Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation.
Fu P; van Heeckeren WJ; Wadhwa PD; Bajor DJ; Creger RJ; Xu Z; Cooper BW; Laughlin MJ; Gerson SL; Koç ON; Lazarus HM
Contemp Clin Trials; 2008 Mar; 29(2):157-64. PubMed ID: 17707140
[TBL] [Abstract][Full Text] [Related]
36. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
37. [Treatment with ACVP-16 for relapsed and refractory non-Hodgkin's lymphoma].
Niitsu N; Hara A; Umeda M; Shirai T
Rinsho Ketsueki; 1993 Jul; 34(7):829-34. PubMed ID: 7689661
[TBL] [Abstract][Full Text] [Related]
38. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
[TBL] [Abstract][Full Text] [Related]
39. Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.
Vitolo U; Orsucci L; Bertini M; Cavallero G; Gallamini A; Ghio R; Levis A; Rota-Scalabrini D; Resegotti L
Haematologica; 1991; 76(1):43-6. PubMed ID: 2055560
[TBL] [Abstract][Full Text] [Related]
40. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]